Prudential Financial’s Mineralys Therapeutics MLYS Stock Holding History

Prudential Financial’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.61M	Sell	59,555 -29,510	-33%	-$865K	﹤0.01%	1407
2025 Q4	$3.23M	Buy	89,065 +38,640	+77%	+$1.55M	﹤0.01%	1085
2025 Q3	$1.91M	Sell	50,425 -301,800	-86%	-$6.53M	﹤0.01%	1367
2025 Q2	$4.77M	Buy	352,225 +224,815	+176%	+$3.26M	0.01%	926
2025 Q1	$2.02M	Buy	127,410 +1,760	+1%	+$20.2K	﹤0.01%	1281
2024 Q4	$1.55M	Buy	125,650 +58,000	+86%	+$758K	﹤0.01%	1409
2024 Q3	$819K	Hold	67,650	–	–	﹤0.01%	1985
2024 Q2	$792K	Buy	+67,650	New	+$852K	﹤0.01%	1963
2023 Q3	–	Sell	-50,770	Closed	-$866K	–	2663
2023 Q2	$866K	Buy	50,770 +200	+0.4%	+$2.99K	﹤0.01%	1874
2023 Q1	$792K	Buy	+50,570	New	+$851K	﹤0.01%	1861

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Prudential Financial's MLYS Position: Q1 2026 in Review

Prudential Financial reduced its Mineralys Therapeutics (MLYS) stake by 33% in Q1 2026, selling an estimated $865K and leaving 59,555 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1407.

Prudential Financial first reported a position in MLYS in Q1 2023 and has held it in 10 quarters since. The position peaked at $4.77M in Q2 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

Prudential Financial held 59,555 shares of Mineralys Therapeutics worth $1.61M as of Q1 2026.
Prudential Financial sold 29,510 Mineralys Therapeutics shares in Q1 2026, an estimated $865K.
Mineralys Therapeutics made up ﹤0.01% of Prudential Financial's portfolio in Q1 2026, its #1407 holding.
Prudential Financial first reported a position in Mineralys Therapeutics in Q1 2023 and has held it in 10 quarters since.
Prudential Financial's Mineralys Therapeutics position peaked at $4.77M in Q2 2025.
214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Prudential Financial's 13F filing for Q1 2026, filed 13 May 2026.